Pfizer Coronavirus Vaccine Protection Lasts At Least Six Months

Further results from ongoing trials also show that the vaccine fully protects recipients from the variant first detected in South Africa.

THE CORONAVIRUS VACCINE developed by Pfizer and BioNTech protects against the virus for at least six months and provides full protection from the variant first detected in South Africa, a version of the virus experts feared would evade vaccine protection.

The companies announced on Thursday more results from the ongoing phase three trial of their vaccine, revealing that recipients of the two-dose vaccine course are protected for at least six months after the second dose, which is longer than the best estimate of 90-day protection initially proposed.

Cartoons on the Coronavirus

View All 536 Images

The vaccine remains 91.3% effective against symptomatic COVID-19 measured seven days through six months after the second dose. While half a year is a modest timeline, the results are just the first look at how long protection from a COVID-19 vaccine lasts.

Recommended Videos
Powered by AnyClip
Pfizer says its vaccine is safe for kids age 12 to 15
628
Play Video

NOW PLAYINGPfizer says its vaccine is safe for kids age 12 to 15
Pfizer says its Covid-19 vaccine protects younger teens
Doctor answers questions about COVID-19 vaccine for kids
Pfizer says vaccine safe, effective on adolescents in trial
Moderna coronavirus vaccine 'adds another string to our bow'

However, the results do raise the question of whether people will need additional booster shots in the future for continued protection against the virus.

Additionally, the phase three results show that the vaccine is completely effective on the concerning variant that it is now the dominant strain in South Africa.

"The high vaccine efficacy observed through up to six months following a second dose and against the variant prevalent in South Africa provides further confidence in our vaccine's overall effectiveness," the companies said.

Albert Bourla, chairman and CEO of Pfizer, said the "data confirm the favorable efficacy and safety profile of our vaccine and position us to submit a Biologics License Application to the U.S. FDA."

A BLA is an application for full approval. Pfizer's vaccine is currently approved in the U.S. for emergency use.

The vaccine also continues to be safe and well tolerated over the six-month period.

"It is an important step to further confirm the strong efficacy and good safety data we have seen so far, especially in a longer-term follow-up," Ugur Sahin, CEO and co-founder of BioNTech, said. "These data also provide the first clinical results that a vaccine can effectively protect against currently circulating variants, a critical factor to reach herd immunity and end this pandemic for the global population."

Alexa Lardieri, Staff Writer

Alexa Lardieri is a reporter and digital producer for the Civic section of U.S. News & World ...  READ MORE

Tags: vaccines, coronavirus

Further results from ongoing trials also show that the vaccine fully protects recipients from the variant first detected in South Africa.

THE CORONAVIRUS VACCINE developed by Pfizer and BioNTech protects against the virus for at least six months and provides full protection from the variant first detected in South Africa, a version of the virus experts feared would evade vaccine protection.

The companies announced on Thursday more results from the ongoing phase three trial of their vaccine, revealing that recipients of the two-dose vaccine course are protected for at least six months after the second dose, which is longer than the best estimate of 90-day protection initially proposed.

Cartoons on the Coronavirus

https://www.loudounbar.org/advert/putlockershd-watch-the-falcon-and-the-winter-soldier-season-1-episode-3-2021-online-full-episodes/
https://chromo.it/forums/topic/the-falcon-and-the-winter-soldier-season-1-episode-3-2021-online-full/
https://sedc.instructure.com/courses/1384595/pages/watch-the-falcon-and-the-winter-soldier-season-1-episode-3-2021-free-download-hd7210p
https://sedc.instructure.com/courses/1384595/pages/dot-watch-dot-the-falcon-and-the-winter-soldier-season-1-episode-3-online-full-episodes-episodes
https://sedc.instructure.com/courses/1384595/pages/official-watch-the-falcon-and-the-winter-soldier-season-1-episode-3-full-episode

The vaccine remains 91.3% effective against symptomatic COVID-19 measured seven days through six months after the second dose. While half a year is a modest timeline, the results are just the first look at how long protection from a COVID-19 vaccine lasts.

Recommended Videos
Powered by AnyClip
Pfizer says its vaccine is safe for kids age 12 to 15
628
Play Video

NOW PLAYINGPfizer says its vaccine is safe for kids age 12 to 15
Pfizer says its Covid-19 vaccine protects younger teens
Doctor answers questions about COVID-19 vaccine for kids
Pfizer says vaccine safe, effective on adolescents in trial
Moderna coronavirus vaccine 'adds another string to our bow'

However, the results do raise the question of whether people will need additional booster shots in the future for continued protection against the virus.

https://sedc.instructure.com/courses/1384595/pages/the-falcon-and-the-winter-soldier-1-ep-3-episode-3-eng-sub-full-episodes
https://sedc.instructure.com/courses/1384595/pages/the-falcon-and-the-winter-soldier-s1-ep-3-episode-3-engsub-full-episodes
https://sedc.instructure.com/courses/1384595/pages/the-falcon-and-winter-soldier-season-1-episode-3-online-full-series
https://sedc.instructure.com/courses/1384595/pages/123movies-series-official-the-falcon-and-the-winter-soldier-season-1-episode-3-online-full-episode
https://sedc.instructure.com/courses/1384595/pages/hd-~123movie-watch-the-falcon-and-the-winter-soldier-season-1-episode-3-2021-online-full
https://www.getrevue.co/profile/Manifest-s3-e1-hd-online

Additionally, the phase three results show that the vaccine is completely effective on the concerning variant that it is now the dominant strain in South Africa.

"The high vaccine efficacy observed through up to six months following a second dose and against the variant prevalent in South Africa provides further confidence in our vaccine's overall effectiveness," the companies said.

Albert Bourla, chairman and CEO of Pfizer, said the "data confirm the favorable efficacy and safety profile of our vaccine and position us to submit a Biologics License Application to the U.S. FDA."

A BLA is an application for full approval. Pfizer's vaccine is currently approved in the U.S. for emergency use.

The vaccine also continues to be safe and well tolerated over the six-month period.

"It is an important step to further confirm the strong efficacy and good safety data we have seen so far, especially in a longer-term follow-up," Ugur Sahin, CEO and co-founder of BioNTech, said. "These data also provide the first clinical results that a vaccine can effectively protect against currently circulating variants, a critical factor to reach herd immunity and end this pandemic for the global population."

Alexa Lardieri, Staff Writer

Alexa Lardieri is a reporter and digital producer for the Civic section of U.S. News & World ...  READ MORE

Tags: vaccines, coronavirus